The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.
Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza).
Age ≥ 18 years at the time of informed consent.
Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation.
Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.
Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding.
Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses.
Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations.
Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable.
Research Center Borstel
Lead sponsor
University Hospital Schleswig-Holstein
Sponsor institution